Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.474
Neutral
RSI(14)
54.671
Neutral
STOCH(KDJ)(9,3,3)
38.294
Sell
ATR(14)
6.994
High Vlolatility
CCI(14)
15.794
Neutral
Williams %R
69.318
Sell
TRIX(12,20)
0.921
Sell
StochRSI(14)
0.000
Sell
Repligen Corp
RGEN151.570USD
-9.530-5.92%
Close 10/28, 16:00（ET）Quotes delayed by 15 min
8.53BMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Repligen Corp
Currency: USD Updated: 2025-10-28Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Repligen Corp's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
22
analysts
Buy
Current Rating
179.513
Target Price
+11.43%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Repligen Corp Highlights
StrengthsRisks
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Undervalued
The company’s latest PE is -608.54, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 55.75M shares, decreasing 9.05% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 1.91M shares of this stock.
Financial Health
Currency: USD Updated: 2025-10-28The company's current financial score is 9.24, which is higher than the Healthcare Equipment & Supplies industry's average of 7.47. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 182.37M, representing a year-over-year increase of 18.36%, while its net profit experienced a year-over-year increase of 347.64%.
Score
Financials
10.00
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
No Data
Quality of Earnings
9.40
Operational Efficiency
10.00
Growth Potential
9.23
Shareholder Returns
7.57
Repligen Corp's Company Valuation
Currency: USD Updated: 2025-10-28The company’s current valuation score is 7.45, which is higher than the Healthcare Equipment & Supplies industry's average of 7.19. Its current P/E ratio is -608.54, which is -267.65% below the recent high of 1020.24 and -92.59% above the recent low of -1172.00.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 15/197
No Data
Earnings Forecast
Currency: USD Updated: 2025-10-28The company’s current earnings forecast score is 8.00, which is higher than the Healthcare Equipment & Supplies industry's average of 7.72. The average price target for Repligen Corp is 180.00, with a high of 220.00 and a low of 130.00.
Score
Support & Resistance
No Data
Analyst Rating
Based on
22
analysts
Buy
Current Rating
179.513
Target Price
+11.43%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
110
Total
7
Median
9
Average
Company name
Ratings
Analysts
Repligen Corp
RGEN
22
Medtronic PLC
MDT
35
Stryker Corp
SYK
33
Abbott Laboratories
ABT
31
Zimmer Biomet Holdings Inc
ZBH
30
Dexcom Inc
DXCM
29
1
2
3
...
22
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
No Data
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-10-28The company’s current price momentum score is 7.22, which is higher than the Healthcare Equipment & Supplies industry's average of 6.99. Sideways: Currently, the stock price is trading between the resistance level at 169.56 and the support level at 133.88, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
160.322
Sell
MA10
156.957
Sell
MA20
152.365
Sell
MA50
133.912
Buy
MA100
128.281
Buy
MA200
135.184
Buy
Institutional Confidence
Currency: USD Updated: 2025-10-28The company’s current institutional recognition score is 10.00, which is higher than the Healthcare Equipment & Supplies industry's average of 6.49. The latest institutional shareholding proportion is 99.10%, representing a quarter-over-quarter decrease of 10.17%. The largest institutional shareholder is The Vanguard, holding a total of 5.07M shares, representing 9.00% of shares outstanding, with 0.88% decrease in holdings.
Score
Institutional Shareholding
No Data
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Roy T. Eddleman UEO
State Street Investment Management (US)
Champlain Investment Partners, LLC
Fidelity Management & Research Company LLC
Invesco Advisers, Inc.
1
2
Risk Assessment
Currency: USD Updated: 2025-10-28The company’s current risk assessment score is 6.93, which is higher than the Healthcare Equipment & Supplies industry's average of 4.64. The company's beta value is 1.15. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.15
VaR
+5.00%
240-Day Maximum Drawdown
+37.51%
240-Day Volatility
+54.37%
Return
Best Daily Return
60 days
+9.08%
120 days
+9.08%
5 years
+17.86%
Worst Daily Return
60 days
-5.92%
120 days
-6.81%
5 years
-13.22%
Sharpe Ratio
60 days
+2.28
120 days
+0.89
5 years
+0.11
Risk Assessment
Maximum Drawdown
240 days
+37.51%
3 years
+47.75%
5 years
+66.41%
Return-to-Drawdown Ratio
240 days
+0.23
3 years
-0.10
5 years
-0.10
Skewness
240 days
+0.05
3 years
+0.45
5 years
+0.23
Volatility
Realised Volatility
240 days
+54.37%
5 years
+50.71%
Standardised True Range
240 days
+4.30%
5 years
+5.11%
Downside Risk-Adjusted Return
120 days
+165.92%
240 days
+165.92%
Maximum Daily Upside Volatility
60 days
+37.87%
Maximum Daily Downside Volatility
60 days
+26.15%
Liquidity
Average Turnover Rate
60 days
+1.43%
120 days
+1.48%
5 years
--
Turnover Deviation
20 days
+4.49%
60 days
+14.60%
120 days
+19.07%
Peer Comparison
Healthcare Equipment & Supplies
Repligen Corp
RGEN
8.16 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cencora Inc
COR
8.64 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Boston Scientific Corp
BSX
8.62 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
LivaNova PLC
LIVN
8.56 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Zimmer Biomet Holdings Inc
ZBH
8.54 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Artivion Inc
AORT
8.50 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
